Cold Agglutinin Disease Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.
The planned total study duration per participant was approximately 1.5 to 2.5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05096403 -
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
|
Phase 3 | |
| Completed |
NCT05132127 -
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
|
Phase 3 | |
| Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
| Completed |
NCT00373594 -
Therapy for Chronic Cold Agglutinin Disease
|
Phase 2 | |
| Recruiting |
NCT05931718 -
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
|
||
| Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
| Completed |
NCT02689986 -
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
|
Phase 2 | |
| Completed |
NCT01303952 -
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
|
Phase 2 | |
| Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 |